全文获取类型
收费全文 | 144篇 |
免费 | 12篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 2篇 |
妇产科学 | 10篇 |
基础医学 | 29篇 |
临床医学 | 18篇 |
内科学 | 19篇 |
神经病学 | 8篇 |
特种医学 | 2篇 |
外科学 | 40篇 |
预防医学 | 11篇 |
眼科学 | 2篇 |
药学 | 4篇 |
肿瘤学 | 10篇 |
出版年
2021年 | 2篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2013年 | 4篇 |
2012年 | 4篇 |
2011年 | 2篇 |
2006年 | 2篇 |
2005年 | 2篇 |
2004年 | 3篇 |
2003年 | 6篇 |
2002年 | 4篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 3篇 |
1996年 | 5篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1978年 | 3篇 |
1975年 | 3篇 |
1972年 | 2篇 |
1960年 | 2篇 |
1945年 | 2篇 |
1934年 | 1篇 |
1929年 | 1篇 |
1928年 | 1篇 |
1926年 | 2篇 |
1922年 | 1篇 |
1921年 | 1篇 |
1918年 | 3篇 |
1917年 | 1篇 |
1916年 | 2篇 |
1915年 | 3篇 |
1914年 | 2篇 |
1913年 | 1篇 |
1910年 | 2篇 |
1909年 | 2篇 |
1908年 | 3篇 |
1907年 | 2篇 |
1906年 | 1篇 |
1905年 | 3篇 |
1904年 | 2篇 |
1901年 | 1篇 |
排序方式: 共有156条查询结果,搜索用时 15 毫秒
91.
92.
B S Coller E Kalomiris M Steinberg L E Scudder 《The Journal of clinical investigation》1984,73(3):794-799
By using a combination of a heterologous antiserum to GPIb/glycocalicin and a radiolabeled monoclonal antibody to GPIb/glycocalicin, we were able to develop a sensitive and specific radioimmunoelectrophoretic assay that can distinguish small amounts of glycocalicin from GPIb. Normal plasmas were found to contain glycocalicin, even in samples treated with protease inhibitors and centrifuged extensively to remove platelets and platelet fragments. Confirmation that the plasma antigen had a relative molecular weight similar or identical to glycocalicin was obtained from studies employing gel chromatography and affinity chromatography. An immunoradiometric assay was developed to quantify plasma glycocalicin, and normal plasma was found to contain approximately 1-3 micrograms/ml. The plasma of a patient with severe thrombocytopenia due to aplastic anemia had less than 12.5% of the normal level of glycocalicin, whereas two patients with thrombocytopenia due to diseases of increased platelet destruction (idiopathic thrombocytopenic purpura and hemolytic-uremic syndrome) had normal levels. Thus, there appears to be ongoing catabolism of platelet GPIb in vivo, and we postulate that the plasma level of glycocalicin reflects a complex function of factors, including platelet count, platelet turnover, and the site of platelet destruction. 相似文献
93.
Geoffrey R. Weiss M.D. P.Y. Liu Ph.D. David S. Alberts M.D. Yei-Mei Peng Ph.D. Emily Fisher M.S. Min Jian Xu M.D. Sidney A. Scudder M.D. Laurence H. Baker D.O. Dennis F. Moore Jr. M.D. Scott M. Lippman M.D. 《Gynecologic oncology》1998,71(3):386-390
Purpose.Preclinical and clinical data support the study of retinoids and interferon-α (IFN-α) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II randomized trial of the Southwest Oncology Group sought to estimate the response rate for IFN-α plus either 13-cis-retinoic acid (13cRA) or all-trans-retinoic acid (ATRA) in women with recurrent cervical SCC.Patients and Methods.Eligibility for this trial required bidimensionally measurable locally recurrent or metastatic squamous or adenosquamous carcinoma of the uterine cervix; SWOG performance status of ≤2; no prior interferon, retinoids, or chemotherapy (except as radiation sensitization). All but two patients were previously treated with surgery, radiation therapy, or both. After randomization, patients received IFN-α-2A (subcutaneous injection; 3 × 106units/m2/day) plus either 13cRA (1 mg/kg/day orally) or ATRA (150 mg/m2/day orally) in two equally divided doses.Results.Total enrollment was 63 patients, 21 in the ATRA arm, 42 in the 13cRA arm. Three patients were ineligible, 1 in the ATRA arm, 2 in the 13cRA arm. Each arm had 1 patient who received no assigned treatment and was not evaluated for response or toxicity. The ATRA/IFN-α response rate was 5% (1/19; 95% confidence interval = 0.1–26%), consisting of 1 partial response lasting 4 weeks. The 13cRA/IFN-α response rate was 8% (3/39; 95% confidence interval = 2–21%), consisting of 3 partial responses lasting 17, 22, and 24 weeks, respectively. All confirmed responses were partial. One additional unconfirmed partial response occurred in the 13cRA arm. Both regimens were generally well-tolerated and produced toxicities (principally malaise and fatigue) associated with each constituent agent's known single-agent side effects.Conclusion.Based upon the results of this study, neither regimen can be recommended for further study in patients previously treated with radiation therapy. 相似文献
94.
95.
96.
97.
Immunohistochemistry for p53, p21(WAF1/CIP1), and Ki-67 provides insight into the molecular events controlling the cell cycle. We tested the hypothesis that these cell cycle markers will aid in the clinical evaluation of ovarian and primary peritoneal surface epithelial neoplasms (SENs). Paraffin sections from a retrospective surgical series of 117 SENs were immunostained with anti-p53 (clone DO7, Novacastra Laboratories, UK), anti-p21(WAF1/CIP1) (clone EA10, Oncogene Science, Cambridge, MA), and anti-Ki-67 (clone MIB-1, Immunotech, Westbrook, ME). The Ki-67 proliferation index (Ki-67PI) and immunoreactivity were evaluated. One hundred seventeen SENs reacted as follows: p53 50%+ and p21(WAF1/CIP1) 65%+. Ki-67PI ranged from 4% to 88% (mean/median = 44/46%). p53 reactivity associated with transitional cell histology, decreased p21(WAF1/CIP1) staining, increased Ki-67PI, architectural/nuclear grade, and stage (P < .05, 1 x 10(-7), .01, .05/.0001, .001,). p21(WAF1/CIP1) staining was associated with endometrioid/clear cell histology, decreased Ki-67PI, architectural/nuclear grade, and stage (P < 05/.05, .05, .01/1 x 10(-8), 1 x 10(-5)). Ki-67PI associated with increased architectural/nuclear grade but not mucinous histology (P < 1 x 10(-5)/1 x 10(-6), .01). Sixty-seven patients had disease at last follow-up; 53 were dead of disease at 0 to 67 months (mean/median, 21/18), and 14 were alive with disease at 12 to 224 months (mean/median, 56/40). Fifty patients were disease free at 5 to 214 months (mean/median, 59/41). Predictors of survival include decreased Ki-67PI, stage, architectural/nuclear grade (P < 1 x 10(-6), 1 x 10(-10), 1 x 10(-10)/.005) and p21(WAF1/CIP1) IMS (multivariate P < 1 x 10(-6)). p21(WAF1/CIP1), a potent inhibitor of cyclin-dependent kinases necessary for cell cycle progression, functions as a key checkpoint in cell cycle control. Immunoreactivity for p21(WAF1/CIP1) provides prognostic information independent of other histological and clinical predictors, p53 IMS, and Ki-67PI in this series of 117 PTs with SENs. Our preliminary data suggest an interrelationship between p21(WAF1/CIP1) expression and an effective clinical response to platinin-based chemotherapy, both associated with apoptosis. Further investigation seems warranted. 相似文献
98.
Timothy J Iveson Rachel S Kerr Mark P Saunders Jim Cassidy Niels Henrik Hollander Josep Tabernero Andrew Haydon Bengt Glimelius Andrea Harkin Karen Allan John McQueen Claire Scudder Kathleen Anne Boyd Andrew Briggs Ashita Waterston Louise Medley Charles Wilson Richard Ellis James Paul 《The lancet oncology》2018,19(4):562-578
99.
100.
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. 总被引:3,自引:5,他引:3 下载免费PDF全文
T Yasuda H K Gold J T Fallon R C Leinbach J L Guerrero L E Scudder M Kanke D Shealy M J Ross D Collen et al. 《The Journal of clinical investigation》1988,81(4):1284-1291
Localized thrombosis was produced in the left anterior descending (LAD) coronary artery of open chest dogs by constricting a segment so as to produce greater than 90% stenosis (reducing blood flow to 40 +/- 10% of baseline), and placing a thrombus in the segment immediately proximal to the stenosis by inducing endothelial cell injury and instilling a mixture of blood and thrombin. Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) at a rate of 15-30 micrograms/kg per min for 30 or 60 min in eight dogs induced coronary artery reperfusion within 23 +/- 7 min (mean +/- SD), but reocclusion occurred despite heparin anticoagulation in all but one of these dogs within 7 +/- 5 min. Intravenous injection of 0.8 mg/kg of the F(ab')2 fragment of a monoclonal antibody (7E3) directed against the platelet GPIIb/IIIa receptor, prevented reocclusion in 10/10 dogs during an observation period of 2 h (P less than 0.001 vs. rt-PA alone). The antibody abolished ADP-induced platelet aggregation and markedly prolonged the bleeding time. Intravenous aspirin or dipyridamole prevented reocclusion for 1 h or more in only 2/7 and 1/6 dogs, respectively. We conclude that the monoclonal antibody is very effective in preventing reocclusion after successful thrombolysis of occluded coronary arteries with rt-PA. 相似文献